Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

On September 3, 2024 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that members of its management team will participate in upcoming investor conferences in September 2024 (Press release, Abeona Therapeutics, SEP 3, 2024, View Source [SID1234646279]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference: Investor meetings on Thursday, September 5, 2024.
H.C. Wainwright Annual Global Investment Conference: Company presentation on Tuesday, September 10, 2024 at 1:30 p.m. ET and investor meetings.
Cantor Global Healthcare Conference: Fireside chat on Thursday, September 19, 2024 at 9:45 a.m. ET and investor meetings.

A live webcast of the presentation and fireside chat can be accessed on the Investors section of the Abeona website under "Events" at View Source, where a replay of the events will also be available for a limited time.

Investor webinar – Azer-cel trial update

On September 3, 2024 Imugene Limited (ASX:IMU), a clinical-stage immuno‐ oncology company, reported that it will hold an investor webinar on Wednesday 4 September 2024 at 10am AEST to discuss the new data from its azer-cel Phase 1b clinical trial in blood cancer Diffuse Large B-Cell Lymphoma (announced 2 September 2024) (Press release, Imugene, SEP 3, 2024, https://mcusercontent.com/e38c43331936a9627acb6427c/files/2d4fea36-e0fc-fc96-87d4-f6aa75112df8/Imugene_Webinar_Azer_cel_Trial_Update.pdf [SID1234646269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenting as part of the webinar will be Imugene’s Managing Director and CEO Leslie Chong, alongside Chief Medical Officer Dr Paul Woodard.

Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link:

View Source

After registering, you will receive a confirmation email with details on how to join the webinar. A recording will be available at the same link shortly after the conclusion of the session.

Median Technologies to host two webcasts on September 5, 2024

On September 2, 2024 Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, "Median" or "The Company") reported that it will host two live webcasts on September 5, 2024 (Press release, MEDIAN Technologies, SEP 2, 2024, View Source [SID1234646271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the recent release of results of the eyonis LCS REALITY study, Fredrik Brag, CEO and Founder of Median Technologies, will offer further insights into the significance of eyonis LCS and discuss the next steps for Median’s novel Software as a Medical Device.

September 5, 2024 – 4:00 pm CEST / 10:00 am EDT (English)
September 5, 2024 – 6:00 pm CEST / 12:00 pm EDT (French)

Webcast replays will be available on Median’s corporate website shortly after the live sessions.

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

On September 2, 2024 Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), reported a collaboration agreement with Shenzhen TargetRx Inc (Press release, Jiangsu Simcere Pharmaceutical Company, SEP 2, 2024, View Source [SID1234646270]). The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China. These rights encompass but are not limited to marketing promotion, strategy formulation and adjustment, and the right to obtain relevant benefits from TGRX-326. TargetRx will receive an initial payment exceeding $20 million. Additionally, TargetRx will compensate Simcere Zaiming for promotional services.

TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor independently developed by TargetRx. It is a potent and highly selective small molecule inhibitor that targets ALK and c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinases (RTKs). This inhibitor holds significant therapeutic potential for ALK/ROS1 fusion gene-positive non-small cell lung cancer (NSCLC) patients, especially those with multiple ALK-resistant mutations, including G1202R.

In preclinical studies and a Phase 1 clinical trial, TGRX-326 demonstrated robust anti-tumor activity and a favorable safety profile. Moreover, the molecule effectively crosses the blood-brain barrier, exhibiting exceptional efficacy in NSCLC patients with brain metastases.

Dr. Renhong Tang, Chairman of Simcere Zaiming, said, "We are pleased to collaborate with TargetRx on novel dual-targeted therapy for lung cancer, a major malignancy that Simcere Zaiming strategically focuses on. This partnership will further enhance our innovative product portfolio. ALK/ROS1 fusion is a critical genetic mutation in non-small cell lung cancer. The advancement of targeted therapies has significantly improved survival rates for these patients. However, there remains a substantial need for new treatments with better efficacy and the ability to overcome drug resistance. We look forward to working closely with TargetRx to provide Chinese lung cancer patients with more effective treatment options as soon as possible."

Dr. Yihan Wang, Chairman of TargetRx, said, "TGRX-326 is a potentially best-in-class novel anti-tumor molecule independently developed by TargetRx. It is a third-generation ALK inhibitor in late-stage clinical development which may bring a better option for patients. We believe that with the support of Simcere Zaiming, we will be able to bring this product quickly to the market. TargetRx aims to continuously deliver innovative therapies that will transform the lives of cancer patients."

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

On September 2, 2024 Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, reported that it has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding competition to support the clinical development of its lead candidate THEO-260 (Press release, Theolytics, SEP 2, 2024, View Source [SID1234646268]). This non-dilutive funding adds to the £19M raised earlier this year from a strong investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and Oxford University Innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Innovate UK, part of UK Research and Innovation, invests in innovative projects that are positioned to advance next-generation immunotherapies for cancer.

The grant will primarily support the Company’s upcoming Phase 1 multi-centre, open-label first-in-human trial to evaluate safety and tolerability of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer and determine the recommended Phase 2 dose. This trial is expected to begin in the coming months.

It will further allow for comprehensive analysis to elucidate and evidence THEO-260’s unique mechanism of action to destroy cancer cells and immune suppressive stromal cells, whilst also inducing T cell activation, through a comprehensive biomarker study, including the development of novel biomarker tests. Proceeds will also support the evolution of Theolytics as it continues to expand its footprint and reach as a clinical-stage oncology biotech company.

"This competitive award from Innovate UK in the category of "Transforming Cancer Therapeutics" reflects the novelty of our research as well as our ability to deliver operational excellence as we move forward to the clinic. This will allow us to precisely demonstrate the mechanism of action of THEO-260, which we anticipate will provide key information to enhance further development of this immunotherapeutic oncolytic virus and our wider platform," said Miriam Bazan Peregrino, Theolytics’ VP Translational Development.

About THEO-260

THEO-260 is a next-generation oncolytic adenovirus for the treatment of ovarian cancer. Positioned to tackle the complex, immune suppressed nature of advanced solid tumours. It demonstrates effective killing of cancer cells and cancer-associated fibroblasts (CAFs), whilst inducing immune activation in advanced preclinical models, including extensive panels of ovarian cancer patient samples. THEO-260 will be evaluated in Phase I clinical trials by intravenous and intraperitoneal delivery to ovarian cancer patients.